RegulatoryAug 7, 2026, 04:07 PM
Niki BioSolutions Regains Nasdaq Minimum Bid Price Compliance
AI Summary
Niki BioSolutions, Inc. (formerly Aptorum Group Limited) announced it has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a deficiency letter on March 5, 2026, for its common stock trading below $1.00 per share for 30 consecutive business days. Nasdaq confirmed on August 4, 2026, that the company's stock closed at or above $1.00 for 10 consecutive business days, thereby resolving the compliance issue.
Key Highlights
- Niki BioSolutions, Inc. regained compliance with Nasdaq's minimum bid price requirement.
- The company previously received a deficiency letter on March 5, 2026, for failing to maintain a $1.00 minimum bid price.
- Nasdaq Listing Rule 5550(a)(2) requires a minimum $1.00 per share closing price for continued listing.
- The compliance period was 180 calendar days, until September 1, 2026.
- On August 4, 2026, Nasdaq confirmed compliance after the stock closed at or above $1.00 for 10 consecutive business days (July 21 - August 3, 2026).
Price Impact
More from APM